Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105


Multimodal Imaging of Nonenhancing Glioblastoma Regions.

John F, Robinette NL, Amit-Yousif AJ, Bosnyák E, Barger GR, Shah KD, Mittal S, Juhász C.

Mol Imaging. 2019 Jan-Dec;18:1536012119885222. doi: 10.1177/1536012119885222.


Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival.

John F, Bosnyák E, Robinette NL, Amit-Yousif AJ, Barger GR, Shah KD, Michelhaugh SK, Klinger NV, Mittal S, Juhász C.

Neuro Oncol. 2019 Feb 14;21(2):264-273. doi: 10.1093/neuonc/noy169.


Tryptophan PET in pretreatment delineation of newly-diagnosed gliomas: MRI and histopathologic correlates.

Kamson DO, Juhász C, Buth A, Kupsky WJ, Barger GR, Chakraborty PK, Muzik O, Mittal S.

J Neurooncol. 2013 Mar;112(1):121-32. doi: 10.1007/s11060-013-1043-4. Epub 2013 Jan 9.


Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.

Boonzaier NR, Larkin TJ, Matys T, van der Hoorn A, Yan JL, Price SJ.

Radiology. 2017 Jul;284(1):180-190. doi: 10.1148/radiol.2017160150. Epub 2017 Feb 27.


Tryptophan PET predicts spatial and temporal patterns of post-treatment glioblastoma progression detected by contrast-enhanced MRI.

Bosnyák E, Kamson DO, Robinette NL, Barger GR, Mittal S, Juhász C.

J Neurooncol. 2016 Jan;126(2):317-25. doi: 10.1007/s11060-015-1970-3. Epub 2015 Oct 29.


Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.

Hayes AR, Jayamanne D, Hsiao E, Schembri GP, Bailey DL, Roach PJ, Khasraw M, Newey A, Wheeler HR, Back M.

Pract Radiat Oncol. 2018 Jul - Aug;8(4):230-238. doi: 10.1016/j.prro.2018.01.006. Epub 2018 Jan 31.


Feasibility of Multimodal MRI-Based Deep Learning Prediction of High Amino Acid Uptake Regions and Survival in Patients With Glioblastoma.

Jeong JW, Lee MH, John F, Robinette NL, Amit-Yousif AJ, Barger GR, Mittal S, Juhász C.

Front Neurol. 2019 Dec 17;10:1305. doi: 10.3389/fneur.2019.01305. eCollection 2019.


Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma.

Harris RJ, Cloughesy TF, Pope WB, Godinez S, Natsuaki Y, Nghiemphu PL, Meyer H, Paul D, Behbahanian Y, Lai A, Ellingson BM.

J Neurooncol. 2013 Apr;112(2):257-66. doi: 10.1007/s11060-013-1057-y. Epub 2013 Jan 24.


Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma.

van Dijken BRJ, Jan van Laar P, Li C, Yan JL, Boonzaier NR, Price SJ; FCRS, van der Hoorn A.

J Neurosurg. 2018 Oct 19;131(3):717-723. doi: 10.3171/2018.5.JNS18340.


Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.

Bosnyák E, Michelhaugh SK, Klinger NV, Kamson DO, Barger GR, Mittal S, Juhász C.

Clin Nucl Med. 2017 May;42(5):341-347. doi: 10.1097/RLU.0000000000001577.


Differential kinetics of α-[¹¹C]methyl-L-tryptophan on PET in low-grade brain tumors.

Juhász C, Muzik O, Chugani DC, Chugani HT, Sood S, Chakraborty PK, Barger GR, Mittal S.

J Neurooncol. 2011 May;102(3):409-15. doi: 10.1007/s11060-010-0327-1. Epub 2010 Jul 30.


Positron emission tomography with α-[11C]methyl-L-tryptophan in tuberous sclerosis complex-related epilepsy.

Rubí S, Costes N, Heckemann RA, Bouvard S, Hammers A, Martí Fuster B, Ostrowsky K, Montavont A, Jung J, Setoain X, Catenoix H, Hino K, Liger F, Le Bars D, Ryvlin P.

Epilepsia. 2013 Dec;54(12):2143-50. doi: 10.1111/epi.12412. Epub 2013 Oct 28.


Tryptophan PET-defined gross tumor volume offers better coverage of initial progression than standard MRI-based planning in glioblastoma patients.

Christensen M, Kamson DO, Snyder M, Kim H, Robinette NL, Mittal S, Juhász C.

J Radiat Oncol. 2014 Jun;3(2):131-138.


Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.

Kong Z, Yan C, Zhu R, Wang J, Wang Y, Wang Y, Wang R, Feng F, Ma W.

Neuroimage Clin. 2018 Jul 5;20:51-60. doi: 10.1016/j.nicl.2018.07.001. eCollection 2018. Review.


Glioma grading by dynamic susceptibility contrast perfusion and 11C-methionine positron emission tomography using different regions of interest.

Brendle C, Hempel JM, Schittenhelm J, Skardelly M, Reischl G, Bender B, Ernemann U, la Fougère C, Klose U.

Neuroradiology. 2018 Apr;60(4):381-389. doi: 10.1007/s00234-018-1993-5. Epub 2018 Feb 20.


Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.

Ken S, Deviers A, Filleron T, Catalaa I, Lotterie JA, Khalifa J, Lubrano V, Berry I, Péran P, Celsis P, Moyal EC, Laprie A.

J Neurooncol. 2015 Sep;124(3):465-73. doi: 10.1007/s11060-015-1860-8. Epub 2015 Jul 19.


FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma.

Lohmann P, Stavrinou P, Lipke K, Bauer EK, Ceccon G, Werner JM, Neumaier B, Fink GR, Shah NJ, Langen KJ, Galldiks N.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):591-602. doi: 10.1007/s00259-018-4188-8. Epub 2018 Oct 16.


Supplemental Content

Support Center